Téma: MOLEKULOVÁ PATOLÓGIA NÁDOROVÝCH OCHORENÍ III.
Číslo abstraktu: 028
Autoři: Mariam Gachechiladze, Ph.D.; MUDr. MVDr. Jozef Škarda, Ph.D.; Mgr. Mária Janíková; Mgr. Giorgi Mgebrishvili; MUDr. Gvantsa Kharaishvili; prof. MUDr. Vítězslav Kolek, DrSc.; MUDr. Ivona Grygárková; prof., MUDr. Jiří Klein, Ph.D., EBSQ; MUDr. Alžběta Poprachová; M. Arabuli; prof. MUDr. Zdeněk Kolář, CSc.
Objective: Resistance to cytotoxic chemotherapeutic drugs represent the major impediment for the successful treatment of non-small cell lung cancer patients. Recently, it has been shown that cytoskeletal protein Filamin A is required for efficient DNA damage repair and modulates cisplatin sensitivity in vitro. We investigated the relationship between the expression levels of filamin A protein and survival outcomes in non-small cell lung cancer patients, treated with adjuvant Carboplatin and Navelbine.
Methods: We analysed filamin A protein expression in resection specimens from 135 non-small cell lung cancer patients, from which 73 patients were treated with adjuvant Carboplatin and Navelbine, and 62 patients did not receive adjuvant treatment. Archived formalin-fixed and paraffin-embedded (FFPE) tissue sections were stained immunohistochemically using EP2405Y antibody against C-terminus of filamin A.
Results: Cox regression analysis of survival showed that increased expression of filamin A protein (histoscore > 90) is significantly related with shorter overall survival (HR = 1,005, 95 % CI (1,000; 1,010), p = 0,037) and disease free survival (HR = 1,004, 95 % CI (1,001: 1,008), p = 0,017) in patients with adjuvant platinum-based chemotherapy. Such relationship was not seen in patients without adjuvant treatment.
Conclusion: Filamin A expression might represent a novel potential predictive marker of platinum-based treatment outcome in patients with non-small-cell lung cancer.
Datum přednesení příspěvku: 5. 6. 2016